176 related articles for article (PubMed ID: 12958606)
41. Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency.
Plantier JL; Rolli V; Ducasse C; Dargaud Y; Enjolras N; Boukerche H; Négrier C
J Thromb Haemost; 2010 Feb; 8(2):286-93. PubMed ID: 19874476
[TBL] [Abstract][Full Text] [Related]
42. Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.
Switzer ME; McKee PA
J Clin Invest; 1977 Oct; 60(4):819-28. PubMed ID: 408379
[TBL] [Abstract][Full Text] [Related]
43. Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis.
Nogami K; Shima M; Giddings JC; Hosokawa K; Nagata M; Kamisue S; Suzuki H; Shibata M; Saenko EL; Tanaka I; Yoshioka A
Blood; 2001 Feb; 97(3):669-77. PubMed ID: 11157483
[TBL] [Abstract][Full Text] [Related]
44. Effects of anti-factor VIII inhibitor antibodies on factor VIIa/tissue factor-catalysed activation and inactivation of factor VIII.
Yada K; Nogami K; Ogiwara K; Shibata M; Shima M
Thromb Haemost; 2011 Jun; 105(6):989-98. PubMed ID: 21437361
[TBL] [Abstract][Full Text] [Related]
45. Fine epitope mapping of monoclonal antibodies to the NH2-terminal part of von Willebrand factor (vWF) by using recombinant and synthetic peptides: interest for the localization of the factor VIII binding domain.
Jorieux S; Gaucher C; Piétu G; Chérel G; Meyer D; Mazurier C
Br J Haematol; 1994 May; 87(1):113-8. PubMed ID: 7524613
[TBL] [Abstract][Full Text] [Related]
46. Inhibition by heparin of thrombin-catalyzed activation of the factor VIII-von Willebrand factor complex.
Barrow RT; Healey JF; Lollar P
J Biol Chem; 1994 Jan; 269(1):593-8. PubMed ID: 8276857
[TBL] [Abstract][Full Text] [Related]
47. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.
d'Oiron R; Lavergne JM; Lavend'homme R; Benhida A; Bordet JC; Negrier C; Peerlinck K; Vermylen J; Saint-Remy JM; Jacquemin M
Blood; 2004 Jan; 103(1):155-7. PubMed ID: 12969981
[TBL] [Abstract][Full Text] [Related]
48. The effect of von Willebrand factor on activation of factor VIII by factor Xa.
Koedam JA; Hamer RJ; Beeser-Visser NH; Bouma BN; Sixma JJ
Eur J Biochem; 1990 Apr; 189(2):229-34. PubMed ID: 2110896
[TBL] [Abstract][Full Text] [Related]
49. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein.
Lenting PJ; Neels JG; van den Berg BM; Clijsters PP; Meijerman DW; Pannekoek H; van Mourik JA; Mertens K; van Zonneveld AJ
J Biol Chem; 1999 Aug; 274(34):23734-9. PubMed ID: 10446132
[TBL] [Abstract][Full Text] [Related]
50. Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding.
Lewis DA; Pound ML; Ortel TL
Thromb Haemost; 2003 May; 89(5):795-802. PubMed ID: 12719775
[TBL] [Abstract][Full Text] [Related]
51. Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain.
Nogami K; Shima M; Giddings JC; Takeyama M; Tanaka I; Yoshioka A
Int J Hematol; 2007 May; 85(4):317-22. PubMed ID: 17483075
[TBL] [Abstract][Full Text] [Related]
52. Effect of von Willebrand Factor and its proteolytic fragments on kinetics of interaction between the light and heavy chains of human factor VIII.
Saenko EL; Loster K; Josic D; Sarafanov AG
Thromb Res; 1999 Dec; 96(5):343-54. PubMed ID: 10605949
[TBL] [Abstract][Full Text] [Related]
53. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
Doshi BS; Gangadharan B; Doering CB; Meeks SL
PLoS One; 2012; 7(10):e48172. PubMed ID: 23144741
[TBL] [Abstract][Full Text] [Related]
54. Domain specific monoclonal anti-factor VIII antibodies generated by inclusion body-renatured factor VIII peptides.
Huang CC; Li LT; Shen MC; Chen JY; Lin SW
Thromb Res; 2001 Mar; 101(5):405-15. PubMed ID: 11297757
[TBL] [Abstract][Full Text] [Related]
55. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.
Dimitrov JD; Roumenina LT; Plantier JL; Andre S; Saboulard D; Meslier Y; Planchais C; Jacquemin M; Saint-Remy JM; Atanasov BP; Kaveri SV; Lacroix-Desmazes S
J Thromb Haemost; 2010 Jul; 8(7):1524-31. PubMed ID: 20374449
[TBL] [Abstract][Full Text] [Related]
56. Activation, activity and inactivation of factor VIII in factor VIII products.
Orfeo T; Elsman R; Gissel M; Mann KG; Butenas S
Haemophilia; 2016 May; 22(3):462-73. PubMed ID: 26822998
[TBL] [Abstract][Full Text] [Related]
57. Immunologic studies of native and modified human factor VIII/von Willebrand factor.
Switzer ME; McKee PA
Blood; 1979 Aug; 54(2):310-21. PubMed ID: 88237
[TBL] [Abstract][Full Text] [Related]
58. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor.
Foster PA; Fulcher CA; Marti T; Titani K; Zimmerman TS
J Biol Chem; 1987 Jun; 262(18):8443-6. PubMed ID: 3110147
[TBL] [Abstract][Full Text] [Related]
59. Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII.
De Cristofaro R; De Filippis V
Biochem J; 2003 Jul; 373(Pt 2):593-601. PubMed ID: 12689334
[TBL] [Abstract][Full Text] [Related]
60. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.
Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP
Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
